FY2025 · period end Dec '25 · from the 10-K filed Feb 19, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $0.21B | negative: -$0.07B | $0.01B | $0.17B | $0.20B |
| Net Income | $0.17B | negative: -$0.10B | negative: -$0.06B | $0.07B | $0.13B |
| EPS (Diluted) | $1.94 | negative: -$1.19 | negative: -$0.73 | $0.79 | $1.53 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B |
| Total Liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B |
| Stockholders' Equity | $0.87B | $0.76B | $0.85B | $0.89B | $0.90B |
| Cash & Equivalents | $0.38B | $0.23B | $0.07B | $0.01B | $0.39B |
| Total Debt | $0.57B | $0.60B | $0.62B | $0.63B | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.27B | $0.21B | $0.14B | $0.17B | $0.08B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | 0.1% | negative: -0.0% | negative: -0.0% | 0.1% | 10.6% |
| Net Margin | 0.1% | negative: -0.0% | negative: -0.0% | 0.0% | 6.9% |
| Return on Equity | 20.3% | negative: -12.3% | negative: -6.9% | 7.4% | 14.6% |
| Return on Assets | 7.5% | negative: -4.5% | negative: -2.6% | 2.6% | 4.8% |
| Debt / Equity | 0.66× | 0.78× | 0.73× | 0.71× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-331488 | Aug 4, 2026 | Aug 4, 2026 | Aug 4, 2026 10:50 UTC | EDGAR |
| 10-Q | 0001193125-26-331513 | Jun 30, 2026 | Aug 4, 2026 | Aug 4, 2026 11:00 UTC | EDGAR |
| 8-K | 0001193125-26-316225 | Jul 21, 2026 | Jul 24, 2026 | Jul 24, 2026 21:00 UTC | EDGAR |
| 8-K | 0001193125-26-304033 | Jul 15, 2026 | Jul 15, 2026 | Jul 15, 2026 11:00 UTC | EDGAR |
| 8-K | 0001193125-26-212117 | May 7, 2026 | May 7, 2026 | May 7, 2026 20:30 UTC | EDGAR |
| 8-K | 0001193125-26-204982 | May 5, 2026 | May 5, 2026 | May 5, 2026 10:50 UTC | EDGAR |
| 10-Q | 0001193125-26-204993 | Mar 31, 2026 | May 5, 2026 | May 5, 2026 11:00 UTC | EDGAR |
| 8-K | 0001193125-26-058063 | Feb 19, 2026 | Feb 19, 2026 | Feb 19, 2026 11:50 UTC | EDGAR |
Direct links to SEC EDGAR. MD has additional filings available on the SEC site.
6 numbers Pediatrix Medical Group, Inc. later changed — same XBRL tag, both filings linked.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q1 2019
Major restatementwas$50.6M
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·Q2 2019
Major restatementwas$52.6M
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·3 months to Dec 2019
Major restatementwas$40.8M
Revised down in a 10-K.
Revenue from Contract with Customer, Including Assessed Tax·Q1 2019
Major restatementwas$851.2M
Revised down in a 10-K. Any P/S built on the original was 99.3% too low.
Revenue from Contract with Customer, Including Assessed Tax·Q2 2019
Major restatementwas$868.3M
Revised down in a 10-K. Any P/S built on the original was 97.7% too low.
Revenue from Contract with Customer, Including Assessed Tax·3 months to Dec 2019
Major restatementwas$905.4M
Revised down in a 10-K. Any P/S built on the original was 97.4% too low.
MD is not the only one.
See every restatement we've found across the market — or get an alert the next time MD revises a number.
Restatements are detected by comparing every vintage of a fact across all of Pediatrix Medical Group, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows MD's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Pediatrix Medical Group, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on MD yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on MD and publish the result to your public profile.
Ask about Pediatrix Medical Group, Inc.
Continue in Workspace — cited answers on MD, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs